DrugGen 2: A disease-aware language model for enhancing drug discovery | Ali Motahharynia et al. | ResearchPod

Transcript: DrugGen 2: A disease-aware language model for enhancing drug discovery

Alex: Welcome to another episode of ResearchPod. Today we're looking at a system called DrugGen-2—an AI designed to help create medicines by considering not just the target protein, but the broader disease environment surrounding it.

Sam: So the paper's argument is that we've been designing drugs in a kind of vacuum—focusing only on the protein while ignoring everything around it?

Alex: Exactly. Think about it this way: a protein in a healthy cell and the same protein in a diseased cell don't behave identically. The disease changes the environment, which changes how the protein acts. So a drug designed only around the protein's general shape might not work as well as one tailored to that specific disease setting.

Sam: It's like fixing a traffic jam—you need to know whether it's caused by an accident or a parade before you can pick the right detour. How does DrugGen-2 actually bring that disease information in?

Alex: They use something called MeSH—Medical Subject Headings. Think of it as a structured library catalog for all of medicine. It organizes diseases, symptoms, and treatments into a hierarchy, showing how concepts relate to one another. So the system doesn't just know "this is a kidney disease." It understands where that disease sits in the broader map of medicine.

Sam: And once it has that map, how does it actually generate a drug molecule?

Alex: It uses a Large Language Model—the same kind of technology that predicts the next word in a text message. But instead of predicting words, it predicts the next piece of a chemical structure, one building block at a time. By feeding it both the disease map and the protein's sequence, the model learns to associate specific chemical patterns with the needs of that exact disease environment.

Sam: That's a useful way to think about it. But how do they stop it from generating chemical nonsense—structures that look plausible on paper but would never work in a real body?

Alex: That's where the training process becomes important. They use a technique called Group Relative Policy Optimization—GRPO for short. Imagine a teacher who gives a class of students the same problem, then grades all their answers together. The students who follow the rules—chemical stability, correct structure, strong binding to the target—get rewarded. The ones who don't, get penalized. Over many rounds of this, the model learns to consistently produce molecules that are both chemically valid and likely to attach firmly to the target protein.

Sam: And binding affinity—that just means how well the drug actually grabs onto the protein it's meant to affect?

Alex: Precisely. A drug that binds weakly might not do much. A drug that binds strongly is more likely to have a real effect. The system is explicitly rewarded for that quality.

DrugGen 2: A disease-aware language model for enhancing drug discovery

Ali Motahharynia, Mohammadreza Ghaffarzadeh-Esfahani, Mahsa Sheikholeslami, Navid Mazrouei, Matin Irajpour, Yousof Gheisari, Hajar Sirous

Jul 9, 2026·4:54·arxiv·Original Paper

DrugGen-2Disease-aware drug discoveryReinforcement Learning (GRPO)Molecular DockingDrug RepurposingDisease-conditioned drug design

Listen

5 min

Briefing

Research Question and Approach

Drug discovery is often limited by a focus on target-based design that ignores the broader disease context. Because the same protein target can have different roles depending on the disease state, the authors developed DrugGen-2, a generative model that incorporates both target protein sequences and disease ontology (using MeSH hierarchies) to design small molecules. The model was built by fine-tuning a pre-trained GPT-2 architecture using a two-step process: supervised fine-tuning on a curated dataset of approved drugs, followed by reinforcement learning via Group Relative Policy Optimization (GRPO). The training was guided by reward functions that prioritized chemical validity, structural novelty, diversity, and high predicted binding affinity.

Main Findings

DrugGen-2 was evaluated against baseline models (DrugGPT and DrugGen) across five protein targets relevant to diabetic nephropathy. The model demonstrated superior performance in several key metrics:

Generation Capacity: It consistently generated a higher number of unique molecules compared to the baselines.
Chemical Quality: The model achieved near-perfect structural validity (99–100%) and produced molecules with higher structural similarity to known approved drugs.
Binding Affinity: Predicted binding affinities were significantly higher across all tested targets. Molecular docking simulations confirmed that several generated ligands achieved binding scores superior to reference drugs like enalapril.

Why It Matters

By integrating disease-specific context into the generative process, DrugGen-2 addresses a critical gap in AI-assisted drug discovery. This approach allows for the design of molecules that are not only optimized for a specific protein target but are also tailored to the biological requirements of a particular disease. This capability is particularly valuable for drug repurposing and de novo design, potentially accelerating the transition from computational hit identification to clinical development by providing more contextually relevant leads.

Key Terms and Definitions

DrugGen-2 — A generative language model that designs small molecules conditioned on both target protein sequences and disease ontology.
Group Relative Policy Optimization (GRPO) — A reinforcement learning technique used to refine the model's output by optimizing for specific reward functions like binding affinity and chemical novelty.
MeSH (Medical Subject Headings) — A comprehensive controlled vocabulary used for indexing and organizing medical information, here utilized to provide disease-specific context to the model.
SMILES (Simplified Molecular Input Line Entry System) — A specification in the form of a line notation for describing the structure of chemical species.
PLAPT (Protein-Ligand Binding Affinity Prediction) — A pre-trained transformer-based model used in this study to estimate the binding strength between generated molecules and target proteins.

Abstract

Current computational approaches for drug design typically focus on generating molecules conditioned on specific targets or general molecular properties, often neglecting the influence of disease context on target behavior and therapeutic outcomes. To address this gap, we introduce DrugGen-2, a novel generative model that designs small molecules conditioned on both disease ontology and target protein sequences. DrugGen-2 was developed by fine-tuning a pre-trained GPT-2 model on a curated dataset of approved drugs linked to their diseases and targets, using a two-step strategy of supervised fine-tuning followed by reinforcement learning via group relative policy optimization (GRPO). This process was guided by reward functions optimizing for chemical validity, novelty, diversity, and high predicted binding affinity. When evaluated on five protein targets relevant to diabetic nephropathy, DrugGen-2 significantly outperformed baseline models (DrugGPT and DrugGen). It demonstrated a superior capacity to generate unique molecules, exhibited greater structural similarity to approved drugs, and achieved improved predicted binding affinities across all targets. Molecular docking analyses further supported these findings, identifying candidate ligands with strong binding potential, including compounds with predicted affinities (-9.917, -9.485, and -9.367) exceeding those of reference drugs such as enalapril for angiotensin-converting enzyme (-8.283). By integrating disease-specific context into molecular generation, DrugGen-2 advances AI-assisted drug discovery, offering a powerful tool for de novo design and drug repurposing that accounts for the complex interplay between diseases and molecular targets.

DrugGen 2: A disease-aware language model for enhancing drug discovery: Research Paper Podcast